"Over the next 3-4 years, we will diversify our entire business from ARV focussed API and formulations to broadly diversified revenue. No therapy will contribute significantly from 2025," said Satyanarayana Chava, Founder and CEO of Laurus Labs in an interview to Moneycontrol.Laurus Labs to focus on non-HIV drugs to drive future growth
"Over the next 3-4 years, we will diversify our entire business from ARV focussed API and formulations to broadly diversified revenue. No therapy will contribute significantly from 2025," said Satyanarayana Chava, Founder and CEO of Laurus Labs in an interview to Moneycontrol.
Subscribe to:
Post Comments (Atom)
-
The NCLT#39;s Ahmedabad bench has directed the RP to include GAIL in the list of creditors for both the companies.
-
"The (latest) investment will be used to grow the mobile esports format and establish presence in select overseas markets through its ...
-
Huawei faces international scrutiny over its ties with the Chinese government and suspicion that Beijing could use Huawei#39;s technology f...
No comments:
Post a Comment